© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On November 26, 2024, we reported on phase 2 data announced by Amgen from a 52-week trial of its investigational maridebart cafraglutide (MariTide) among people with obesity or overweight with or without type 2 diabetes (T2D).
The study
MariTide is a bispecific glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist being investigated for the treatment of obesity and T2D. The phase 2 study (NCT05669599) enrolled 592 adults with obesity or overweight into 2 cohorts:
A: Participants without T2D (n=465)
B: Participants with T2D (n=127)
Participants in cohort A were assigned to 1 of 4 monthly fixed dose arms (placebo, 140 mg, 280 mg, 420 mg) or an 8-week 420 mg dose arm. There were also 2 dose escalation arms with either 4-week or 12-week dose escalation periods to a target dose of 420 mg. Adults in cohort B were assigned to one of the 4 monthly fixed dose arms.
The findings
Results showed that among cohort A (participants with obesity or overweight without T2D), maridebart cafraglutide demonstrated up to approximately 20% average weight loss at week 52. In people with obesity or overweight with T2D (cohort B), MariTide achieved up to approximately 17% average weight loss while also delivering significant improvements in glycemic control, with hemoglobin A1C (HbA1C) levels reduced by up to 2.2 percentage points at week 52. In both study populations, researchers did not observe a weight loss plateau, suggesting the potential for further weight loss beyond the study period.
Related Content:
